Erratum: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis (Neuro-Oncology Advances DOI: 10.1093/noajnl/vdaa082)

Iyad Alnahhas, Mouaz Alsawas, Appaji Rayi, Joshua D. Palmer, Raju Raval, Shirley Ong, Pierre Giglio, Mohammad Hassan Murad, Vinay Puduvalli

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the originally published version of this manuscript, there was an error in co-author Mohammad Hassan Murad's name. The full name should read: "Mohammad Hassan Murad" instead of "Hassan M. Murad". This error has now been corrected online.

Original languageEnglish (US)
Article numbervdab095
JournalNeuro-Oncology Advances
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2021

ASJC Scopus subject areas

  • Clinical Neurology
  • Oncology
  • Surgery

Fingerprint

Dive into the research topics of 'Erratum: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis (Neuro-Oncology Advances DOI: 10.1093/noajnl/vdaa082)'. Together they form a unique fingerprint.

Cite this